PACS
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/E 27.50, PEG 1.02, Graham $12.88
- PEG ratio near 1.0
- Forward P/E is attractive
- Trades far above Graham Number ($12.88)
- High Price/Book (5.55)
Ref Growth rates and Analyst Targets
- 57.2% YoY Earnings growth
- 12.4% Revenue growth
- Strong analyst target price ($45.83)
- Dependence on maintaining high growth to justify premium
Ref Historical earnings surprises and price performance
- Massive 1Y and 6M price returns
- Poor earnings surprise history
- High volatility in quarterly EPS
Ref Piotroski F-Score and Debt/Equity
- Piotroski F-Score 4/9 (Stable)
- Debt/Equity 3.78 is very high
- Current ratio 1.07 is barely adequate
Ref Yield 0%
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PACS and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PACS
PACS Group, Inc.
Primary
|
+45.9% | +45.9% | +248.4% | +174.1% | +4.5% | -4.3% |
|
CAI
Caris Life Sciences, Inc.
Peer
|
-33.0% | -33.0% | -33.0% | -40.6% | -1.3% | +4.9% |
|
LNTH
Lantheus Holdings, Inc.
Peer
|
+283.6% | -6.7% | -18.2% | +50.5% | -2.5% | +5.9% |
|
OSCR
Oscar Health, Inc.
Peer
|
-18.9% | +168.3% | +41.9% | +2.0% | +60.9% | +12.4% |
|
ALKS
Alkermes plc
Peer
|
+53.2% | +17.7% | +17.2% | +7.2% | +11.8% | -0.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PACS
PACS Group, Inc.
|
NEUTRAL | $5.27B | 27.5 | 23.0% | 3.6% | $33.55 | |
|
CAI
Caris Life Sciences, Inc.
|
NEUTRAL | $5.3B | - | -45.4% | -8.4% | $18.75 | Compare |
|
LNTH
Lantheus Holdings, Inc.
|
NEUTRAL | $5.25B | 23.63 | 21.4% | 15.2% | $80.59 | Compare |
|
OSCR
Oscar Health, Inc.
|
BEARISH | $5.56B | - | -44.4% | -3.8% | $18.46 | Compare |
|
ALKS
Alkermes plc
|
NEUTRAL | $5.62B | 23.57 | 14.7% | 16.4% | $33.71 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-24 | MITCHELL JOHN TODD | Officer | Stock Award | 82,039 | - |
| 2026-03-24 | MURRAY JASON HULSE | Chief Executive Officer | Stock Award | 234,397 | - |
| 2026-03-24 | JERGENSEN JOSHUA | President | Stock Award | 146,498 | - |
| 2026-03-24 | LEWIS MICHELLE RENEE | Officer | Stock Award | 35,159 | - |
| 2026-03-24 | HANCOCK MARK | Chief Financial Officer | Stock Award | 98,154 | - |
| 2026-03-24 | PRIEGNITZ KELLY | Officer | Stock Award | 8,203 | - |
| 2026-03-24 | BINGHAM TRENT DEAN | Officer | Stock Award | 14,649 | - |
| 2026-03-13 | JERGENSEN JOSHUA | President | Sale | 36,335 | $1,245,647 |
| 2026-03-05 | HANCOCK MARK | Officer, Director and Beneficial Owner | Gift | 300,000 | - |
| 2026-03-04 | CONWAY PATRICK HUGH M.D. | Director | Stock Award | 3,497 | - |
| 2026-03-03 | PRIEGNITZ KELLY | Officer | Stock Award | 30,000 | - |
| 2026-03-03 | BINGHAM TRENT DEAN | Officer | Stock Award | 25,000 | - |
| 2025-12-19 | DILSAVER EVELYN S | Director | Stock Award | 4,399 | - |
| 2025-12-19 | MILLARD JACQUELINE | Director | Stock Award | 4,399 | - |
| 2025-12-19 | LEAVITT TAYLOR | Director | Stock Award | 4,399 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
PACS operates 314 post-acute care facilities across 17 states, utilizing a strategy of converting underperforming custodial centers into high-value transitional care facilities, with mature sites achieving a 94% occupancy rate and a 4.3 QM Star rating as of December 31, 2024. The company faces significant risks stemming from its dependence on third-party payor reimbursements and potential volatility related to changes in patient acuity mix and payment methodologies.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning PACS from our newsroom.